EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

RATIONALE FOR BASIC FGF IN WOUND HEALING AND REVIEW OF THERAPEUTIC APPLICATIONS

*Luca Spaccapelo, MD

ABSTRACT

Several scientific groups are evaluating the opportunity to develop basic fibroblast growth factor (bFGF) for ophthalmic and other uses. While a number of clinical studies with growth factors have been conducted in the United States and Europe, most experience of bFGF appears to derive from studies in Japan and China, where products based on bFGF have been marketed for more than a decade, primarily for cutaneous wound healing, but also involving studies in bone regrowth and periodontal procedures; relatively less data are available in the open literature regarding ophthalmological use in humans. In Asia, many cytokines are currently under development, including TGF-, EGF, and IGF-1 aside from the already marketed Fiblast Spray® (Japan) and the Beifushu series from Essex Biotechnology Ltd (China). A general concern with all growth factor-based therapies is promotion of tumour growth; in animal models, bFGF injected at the tumour inoculation site induce marked tumour growth and lymph node metastasis, correlating with an increase in neovascularization in the host stroma. Increased mortality from malignancies has been reported in patients treated with becaplermin, also involving tumours distant from the site of application. These concerns are likely to be more pronounced in relation to systemic treatment approaches (i.e. cardiovascular, bone fractures), even though the permanence of systemically administered FGF is likely to be short in the circulation. Specifically in the case of ophthalmological use, another general concern of growth factor therapy is corneal neovascularisation, which would represent an absolute contraindication of FGF therapy for corneal lesions. Against this background, it may be concluded that bFGF may have therapeutic utility in cutaneous wound healing and plastic surgery, while the ophthalmic utility appears less substantiated by published data, where no specific advantages of bFGF treatment have appeared as compared to current standard of care. The concerns regarding tumour promotion likely represent a significant hurdle, and may preclude systemic use (cardiovascular; bone healing) until large-scale and long-term safety studies have been completed to allow a more stringent risk/benefit analysis.

Keywords: fibroblast growth factor, wound healing, corneal neovascularisation, cytokines, becaplermin.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 November 2021 Issue has been Published, Kindly check it on http://www.ejpmr.com/home/current_issues

  • EJPMR: NOVEMBER ISSUE PUBLISHED

    NOVEMBER Issue has been successfully launched on 1 November 2021.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI )